Pulse Biosciences (NASDAQ:PLSE) Releases Earnings Results

Key Points

• Pulse Biosciences reported a quarterly loss of ($0.28) EPS, missing analyst expectations of ($0.26) by $0.02.
• Despite the earnings miss, PLSE stock rose by 1.5% to $15.10 in midday trading, with 171,774 shares changing hands.
• Analysts from Oppenheimer have initiated coverage with an "outperform" rating and set a target price of $22.00 for the stock.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02), Zacks reports.

Pulse Biosciences Trading Up 1.5%

PLSE stock traded up $0.22 during midday trading on Tuesday, reaching $15.10. 171,774 shares of the company's stock traded hands, compared to its average volume of 171,180. The company has a 50-day simple moving average of $15.53 and a two-hundred day simple moving average of $17.00. Pulse Biosciences has a 1-year low of $13.77 and a 1-year high of $25.00.

Analyst Ratings Changes

Separately, Oppenheimer initiated coverage on Pulse Biosciences in a report on Monday, July 7th. They issued an "outperform" rating and a $22.00 target price for the company.

Insiders Place Their Bets

In related news, CTO Darrin Uecker sold 15,000 shares of the firm's stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $16.40, for a total transaction of $246,000.00. Following the completion of the sale, the chief technology officer directly owned 137,872 shares of the company's stock, valued at $2,261,100.80. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 71.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pulse Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning increased its stake in shares of Pulse Biosciences by 26.3% in the 2nd quarter. Creative Planning now owns 18,971 shares of the company's stock valued at $286,000 after buying an additional 3,951 shares during the period. Legal & General Group Plc increased its stake in shares of Pulse Biosciences by 57.7% in the 2nd quarter. Legal & General Group Plc now owns 22,415 shares of the company's stock valued at $338,000 after buying an additional 8,197 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Pulse Biosciences in the 1st quarter valued at $323,000. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.